A new study designs drugs that bind to intrinsically disordered proteins that are extremely difficult to target due to their flexible nature.
Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...
Automated Portal-Enabled Elicitation of Health-Related Patient Values in Solid Tumor Oncology: Feasibility and Patient Characteristics Associated With Patient Response The following represents ...
Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...
A meta-analysis involving 21,260 patients with advanced or metastatic prostate cancer confirms increased risks of falls and fractures with the addition of androgen receptor signaling inhibitors to ...
ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.
The dinuclear platinum(II) complexes inhibit prostate cancer cell growth by binding to the androgen receptor (AR) and disrupting AR-mediated gene expression. This mechanism leads to apoptosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results